Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis
Momelotinib showed a favorable safety profile vs fedratinib, including significantly lower risks of key hematologic and gastrointestinal AEs - such as anemia, diarrhea, and nausea - over 24 weeks.
Authors
- Francesca Palandri (ORCID: https://orcid.org/0000-0001-8367-5668)
- Boris Gorsh (ORCID: https://orcid.org/0000-0001-6977-0220)
- Catherine Elizabeth Ellis (ORCID: https://orcid.org/0009-0008-7635-7846)
- Ruben A. Mesa (ORCID: https://orcid.org/0000-0001-5880-7972)
- James Signorovitch (ORCID: https://orcid.org/0000-0002-4067-8962)
- Gautam Sajeev (ORCID: https://orcid.org/0000-0002-1827-8938)
- Ryan Simpson
- Sang Cho
- Lucia Masárová (ORCID: https://orcid.org/0000-0001-6624-4196)
- Srđan Verstovšek (ORCID: https://orcid.org/0000-0002-6912-8569)
- Claire Harrison
- Zhaohui Wang (ORCID: https://orcid.org/0000-0003-4357-9780)
- S. Conlon
Institutions
- BG Group (United Kingdom) (GB)
- Atrium Health Wake Forest Baptist (US)
- The University of Texas MD Anderson Cancer Center (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- GlaxoSmithKline (United States) (US)
- Azienda USL di Bologna (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Wake Forest Baptist Comprehensive Cancer Center
- Analysis Group (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1080/14796694.2025.2511564
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- GlaxoSmithKline